Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1870 1
1880 1
1884 1
1887 1
1946 1
1947 3
1948 2
1950 1
1952 2
1953 1
1954 2
1955 2
1956 2
1957 1
1958 3
1959 3
1960 3
1961 2
1962 4
1963 3
1964 7
1965 2
1966 4
1967 5
1968 7
1969 3
1970 13
1971 11
1972 16
1973 4
1974 12
1975 7
1976 9
1977 7
1978 14
1979 7
1980 10
1981 7
1982 12
1983 9
1984 9
1985 10
1986 9
1987 9
1988 8
1989 5
1990 3
1991 9
1992 5
1993 6
1994 6
1995 6
1996 6
1997 5
1998 3
1999 4
2000 12
2001 8
2002 15
2003 9
2004 6
2005 14
2006 16
2007 13
2008 20
2009 17
2010 18
2011 29
2012 24
2013 30
2014 21
2015 31
2016 30
2017 40
2018 44
2019 52
2020 57
2021 65
2022 47
Text availability
Article attribute
Article type
Publication date

Search Results

851 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: hamilton e. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
HER2-Low Breast Cancer: Pathological and Clinical Landscape.
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, Andrè F, Curigliano G. Tarantino P, et al. Among authors: hamilton e. J Clin Oncol. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. J Clin Oncol. 2020. PMID: 32330069 Review. No abstract available.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cortés J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P; monarchE Committee Members and Investigators. Johnston SRD, et al. Among authors: hamilton e. J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. J Clin Oncol. 2020. PMID: 32954927 Free PMC article. Clinical Trial.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Murthy RK, et al. Among authors: hamilton e. N Engl J Med. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. N Engl J Med. 2020. PMID: 31825569 Clinical Trial.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N, Rastogi P, Martin M, Tolaney SM, Shao ZM, Fasching PA, Huang CS, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, Sohn J, Guarneri V, Cortés J, Hamilton E, André V, Wei R, Barriga S, Sherwood S, Forrester T, Munoz M, Shahir A, San Antonio B, Nabinger SC, Toi M, Johnston SRD, O'Shaughnessy J; monarchE Committee Members. Harbeck N, et al. Among authors: hamilton e. Ann Oncol. 2021 Dec;32(12):1571-1581. doi: 10.1016/j.annonc.2021.09.015. Epub 2021 Oct 14. Ann Oncol. 2021. PMID: 34656740 Free article. Clinical Trial.
Integrating genomic features for non-invasive early lung cancer detection.
Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, Liu CL, Hui AB, Jin MC, Azad TD, Almanza D, Jeon YJ, Nesselbush MC, Co Ting Keh L, Bonilla RF, Yoo CH, Ko RB, Chen EL, Merriott DJ, Massion PP, Mansfield AS, Jen J, Ren HZ, Lin SH, Costantino CL, Burr R, Tibshirani R, Gambhir SS, Berry GJ, Jensen KC, West RB, Neal JW, Wakelee HA, Loo BW Jr, Kunder CA, Leung AN, Lui NS, Berry MF, Shrager JB, Nair VS, Haber DA, Sequist LV, Alizadeh AA, Diehn M. Chabon JJ, et al. Among authors: hamilton eg. Nature. 2020 Apr;580(7802):245-251. doi: 10.1038/s41586-020-2140-0. Epub 2020 Mar 25. Nature. 2020. PMID: 32269342 Free PMC article.
Targeting HER2 heterogeneity in breast cancer.
Hamilton E, Shastry M, Shiller SM, Ren R. Hamilton E, et al. Cancer Treat Rev. 2021 Nov;100:102286. doi: 10.1016/j.ctrv.2021.102286. Epub 2021 Sep 2. Cancer Treat Rev. 2021. PMID: 34534820 Review.
Targeting CDK4/6 in patients with cancer.
Hamilton E, Infante JR. Hamilton E, et al. Cancer Treat Rev. 2016 Apr;45:129-38. doi: 10.1016/j.ctrv.2016.03.002. Epub 2016 Mar 8. Cancer Treat Rev. 2016. PMID: 27017286 Free article. Review.
Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition.
Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Nabet BY, et al. Among authors: hamilton eg. Cell. 2020 Oct 15;183(2):363-376.e13. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct 1. Cell. 2020. PMID: 33007267 Free PMC article.
851 results